Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia

Equality Impact Assessment (Guidance development) (PDF 229 KB)

Final appraisal determination

Final appraisal determination document (PDF 380 KB)

Committee papers (PDF 1.13 MB)

Final matrix (PDF 96 KB)

Final scope (PDF 62 KB)

Final appraisal determination document TA251 (PDF 735 KB)

Committee papers TA251 (PDF 2.71 MB)

Committee papers (PDF 15.03 MB)

Appraisal consultation document TA251 (PDF 669 KB)

Final scope TA251 (PDF 212 KB)

Final matrix TA251 (PDF 66 KB)

Draft scope and provisional matrix comments table (post-referral) TA251 Draft scope comments (PDF 387 KB)

Draft scope and provisional matrix comments table (post-referral) TA251 Draft matrix comments (PDF 252 KB)